Harrington P, Dillon R, Radia D, Rousselot P, McLornan DP, Ong M, Green A, Verde A, Hussain F, Raj K, Kordasti S, Harrison C, de Lavallade H. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia. Haematologica 2023;108(6):1555-1566; https://doi.org/10.3324/haematol.2022.282005.